In the dynamic landscape of biopharmaceutical innovation, Lee’s Pharmaceutical Holdings Limited stands as a beacon of progress, driven by a profound commitment to addressing unmet medical needs and enhancing patient quality of life.

Founded in 1994, the company has evolved into a leading research-driven and market-oriented biopharmaceutical firm with a significant footprint in China and an expanding global presence. Dr. Benjamin Li, Founder and Director of Lee’s Pharmaceutical Holdings Limited, articulates the company’s core philosophy with clarity and conviction. “We remain committed to the R&D of innovative products to address unmet medical needs and improve patients’ quality of life,” he states.

Dr. Benjamin Li, Founder and Director of Lee's Pharmaceutical Holdings Limited
Dr. Benjamin Li, Founder and Director of Lee's Pharmaceutical Holdings Limited
Production Facility of Lee's Pharmaceutical in Nansha, China
Production Facility of Lee's Pharmaceutical in Nansha, China

This dedication is not merely a corporate slogan but a guiding principle that has shaped Lee’s Pharmaceutical’s extensive portfolio and strategic direction. The company’s robust infrastructure encompasses drug development, clinical development, regulatory affairs, manufacturing, sales, and marketing, all operating with a global perspective from its headquarters in Hong Kong Science Park and production facilities in Nansha and Hefei, China.

A Diverse and Impactful Therapeutic Portfolio

The company’s impact is evident in its focus on several critical therapeutic areas, including cardiovascular health, women’s health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. Their product pipeline boasts over 40 products in various stages of development, a testament to both internal research and development efforts and strategic licensing agreements with international partners from the United States, Europe, and Japan.
A recent landmark achievement underscores Lee’s Pharmaceutical’s relentless pursuit of innovation: the acquisition of the Staccato® One-Breath Technology® platform and its associated assets. This strategic move, executed through Nova Pneuma Inc. (NPI), a wholly-owned subsidiary, grants Lee’s Pharmaceutical full ownership of this proprietary and well-validated drug delivery technology. The Staccato® OBT® platform is revolutionary, capable of delivering excipient-free drugs as rapidly as intravenous injection but through a non-invasive, single-breath inhalation. This rapid onset of therapeutic effect makes it ideally suited for acute conditions requiring immediate relief.

Dr. Li emphasizes the transformative nature of this acquisition. “Acquiring the Staccato® OBT® platform is a transformative step for Lee’s Pharmaceutical, reinforcing our commitment to innovation in inhalation therapeutics targeting CNS and neurodegenerative disorders, and expanding our global footprint,” he remarked. The acquisition not only strengthens Lee’s Pharmaceutical’s inhalation R&D capabilities and pipeline but also creates new revenue streams through strategic partnerships, notably with UCB.
The Staccato® acquisition brings significant synergies to Lee’s Pharmaceutical’s existing product pipeline. The company has already been advancing the clinical development of a Staccato®-based medicine for cancer-related breakthrough pain and has commercialized Adasuve® for acute agitation in adult schizophrenia or bipolar I disorder across Greater China.

corre
Adasuve_box_mockup-device
圖片1
Ferrer_I+D_staccato_0

The elimination of licensing payment obligations to Alexza for these products post-acquisition will lead to immediate cost savings and enhanced economic benefits. Furthermore, two promising CNS pipeline assets targeting Parkinson’s disease and Cyclic Vomiting Syndrome (CVS), both in Phase 2 clinical trials, will be integrated into Lee’s Pharmaceutical’s portfolio, opening new commercial avenues.
Crucially, the acquisition also includes Alexza’s rights and obligations under the existing worldwide licensing and manufacturing supply agreement with UCB. Under this global partnership, UCB retains the development and commercialization rights for Staccato® alprazolam, currently in Phase 3 clinical trials. This reinforces the clinical maturity and commercial potential of the Staccato® OBT® platform. Lee’s Pharmaceutical, through NPI, stands to receive milestone payments totaling up to US$60.5 million and tiered royalties on global net sales of Staccato® alprazolam, in addition to manufacturing revenue.

A Vision Rooted in Compassionate Care

Dr. Li’s vision extends beyond commercial success; it is deeply rooted in compassionate care. He highlights the development of practical solutions, such as a liquid medicine for ALS patients who cannot swallow pills, significantly improving their quality of life. He also expresses immense pride in life-saving products like a nitric oxide treatment for newborns with pulmonary hypertension. His guiding principle, “Rare disease is rare, but the love is not rare,” powerfully encapsulates Lee’s Pharmaceutical’s dedication to even small patient populations, ensuring that groundbreaking medical solutions reach those who need them most.

Looking ahead, Lee’s Pharmaceutical is poised for continued growth and expansion. Dr. Li envisions extending their reach from China and Hong Kong into Southeast Asian markets such as Thailand and Indonesia. The anticipation of a forthcoming oncology drug for cervical cancer, which has demonstrated remarkable results in clinical trials, further exemplifies the company’s commitment to pioneering new treatments.
Lee’s Pharmaceutical, under the steadfast leadership of management, is not just developing drugs; it is revolutionizing healthcare through innovative research, strategic acquisitions, and a compassionate vision for a healthier future. Their journey is a testament to the power of dedication in transforming medical possibilities into tangible improvements for patients worldwide.
The Mediazone Group congratulates Lee’s Pharmaceutical Holdings Limited for winning the Hong Kong’s Most Valuable Companies 2026 Award. We wish the company greater success in its endeavor to deliver innovative and ground-breaking healthcare solutions to our region. For more information visit https://www.leespharm.com